Access

Letter

Nature 444, 217-220 (9 November 2006) | doi:10.1038/nature05263; Received 21 August 2006; Accepted 21 September 2006; Published online 15 October 2006

Open Innovation Challenges

naturejobs

Structure of C3b in complex with CRIg gives insights into regulation of complement activation

Christian Wiesmann1, Kenneth J. Katschke2, JianPing Yin1, Karim Y. Helmy2, Micah Steffek3, Wayne J. Fairbrother1, Scott A. McCallum1, Lizette Embuscado4, Laura DeForge4, Philip E. Hass3 & Menno van Lookeren Campagne2

  1. Department of Protein Engineering,
  2. Department of Immunology,
  3. Department of Protein Chemistry,
  4. Department of Assay Technology, , 1 DNA Way, South San Francisco, California 94080, USA

Correspondence to: Menno van Lookeren Campagne2 Correspondence and requests for materials should be addressed to C.W. (Email: wiesmann.christian@gene.com) or M.v.L.C. (Email: menno@gene.com). Coordinates and structure factors have been deposited at the RCSB Protein Databank (2ICC, 2ICE, and 2ICF).

Top

The complement system is a key part of the innate immune system, and is required for clearance of pathogens from the bloodstream1. After exposure to pathogens, the third component of the complement system, C3, is cleaved to C3b which, after recruitment of factor B, initiates formation of the alternative pathway convertases2, 3, 4. CRIg, a complement receptor expressed on macrophages, binds to C3b and iC3b mediating phagocytosis of the particles5, but it is unknown how CRIg selectively recognizes proteolytic C3-fragments and whether binding of CRIg to C3b inhibits convertase activation. Here we present the crystal structure of C3b in complex with CRIg and, using CRIg mutants, provide evidence that CRIg acts as an inhibitor of the alternative pathway of complement. The structure shows that activation of C3 induces major structural rearrangements, including a dramatic movement (>80 Å) of the thioester-bond-containing domain through which C3b attaches to pathogen surfaces. We show that CRIg is not only a phagocytic receptor, but also a potent inhibitor of the alternative pathway convertases. The structure provides insights into the complex macromolecular structural rearrangements that occur during complement activation and inhibition. Moreover, our structure–function studies relating the structural basis of complement activation and the means by which CRIg inhibits the convertases provide important clues to the development of therapeutics that target complement.

  1. Department of Protein Engineering,
  2. Department of Immunology,
  3. Department of Protein Chemistry,
  4. Department of Assay Technology, , 1 DNA Way, South San Francisco, California 94080, USA

Correspondence to: Menno van Lookeren Campagne2 Correspondence and requests for materials should be addressed to C.W. (Email: wiesmann.christian@gene.com) or M.v.L.C. (Email: menno@gene.com). Coordinates and structure factors have been deposited at the RCSB Protein Databank (2ICC, 2ICE, and 2ICF).

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Immunology Exposure of an executioner

Nature News and Views (09 Nov 2006)

Immunology Exposure of an executioner

Nature News and Views